No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
SCI Pharmtech, Inc., founded in 1987 and based in Taoyuan City, Taiwan, specializes in the comprehensive lifecycle of pharmaceutical components. The company's core operations involve the research and development, manufacturing, and global distribution of active pharmaceutical ingredients (APIs), chemical intermediates, and specialty chemicals. Its extensive portfolio of APIs includes critical compounds such as Articaine HCl, Atomoxetine HCl, Bisoprolol Fumarate, Brinzolamide, Cannabidiol, and Dexmethylphenidate HCl, among many others. Additionally, SCI Pharmtech produces a wide array of intermediate products, featuring substances like Azetidin-3-ol hydrogenchloride, Diethyl Isobutyl Malonate, Pyrogallolaldehyde, and various specialized esters and alcohols, which serve as essential building blocks in chemical synthesis. Beyond its standard product lines, the company also offers custom manufacturing services tailored to specific client needs. SCI Pharmtech maintains a robust international presence, distributing its products to significant markets across the globe, including Italy, China, the United States, Germany, Taiwan, Switzerland, Spain, Japan, and the Netherlands.
www.sci-pharmtech.com.twNo one on the platform currently holds 4119.TW.
No tracked institution reports a position in 4119.TW as of their last filing.
No one on the platform has traded 4119.TW yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 2.6% | 3.5% | 8.8% | — | — | — |
| Rev. Growth % | -11.8% | -13.0% | ||||
| Profit Margin % | 8.0% | 21.7% | 20.6% | |||
| Free Cash Flow Margin % | -29.0% | -51.3% | -16.0% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $1.4B | +6.8% | $0.97 | $0.97–$0.97 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 2 of the last 6 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-03-05 | $0.42 | $0.33 | -21.4% |
| 2025-11-07 | $0.47 | $0.12 | -74.5% |
| 2025-08-07 | $0.37 | $0.19 | -48.6% |
| 2025-05-09 | $0.26 | $0.27 | +3.8% |
| 2025-03-10 | $0.61 | $0.39 | -36.4% |
| 2024-11-08 | $0.48 | $3.19 | +561.3% |
| -0.39% |
| $5.7B |
| — |
| 4126.TWOPacific Hospital Supply Co., Ltd | $77.60 | -0.13% | $5.6B | — |
| 4166.TWOOrient Pharma Co., Ltd. | $23.90 | +0.42% | $5.8B | — |
Source: Financial Modeling Prep · peers by sector/industry